profit from every $100 of sales.
$0$100
YD Bio Limited Warrants
$0.51-1.54% today
-75.1% in 1 year
1-year low $0.221-year high $2.20
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
YD Bio Limited Warrants vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| YD Bio Limited Warrants | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads YD Bio Limited Warrants's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- 0.01
- -6.2×
- 0.0×
- –
- –
- -489.8%
- -29.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -9.3%
- 66.3%
- 80.8%
- -37.5%
- -9.3%
- –
Growth
- –
- –
- −69.3%
- –
- +46.1%
Financial health
- 1.2×
- -0.00
- 0.0%
- –
- 5.88
- 4.74
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 964
Bottom 19%of 898
News
E-L Financial Corporation Limited PFD 1ST SER 3 declares CAD 0.3438 dividendSeeking Alpha · Nov 11, 2026E-L Financial Corporation Limited PFD 1ST SER 1 declares CAD 0.3312 dividendSeeking Alpha · Nov 11, 2026E-L Financial Corporation Limited PFD 4.75% SR 2 declares CAD 0.2968 dividendSeeking Alpha · Nov 11, 2026New England Realty Associates Limited Partnership declares $0.40 dividendSeeking Alpha · Nov 9, 2026Johnson & Johnson (JNJ): Limited Analyst Upside, but Management Sees a Clearer Path to GrowthYahoo Finance · Nov 8, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
45No pass
Philip Fisher
43No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
46No pass
Terry Smith
47No pass
Questions about YD Bio Limited Warrants
Is YD Bio Limited Warrants a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the YD Bio Limited Warrants AI analysis
What does YD Bio Limited Warrants do?
YD Bio Ltd. engages in the development of detection and therapeutic technologies. It offers cancer detection products, regenerative ophthalmology products, and exosome science. The company was founded on February 6, 2024 and is headquartered in Taipei, Taiwan. It is in Biotechnology.
Does YD Bio Limited Warrants pay a dividend?
No. YD Bio Limited Warrants does not pay a dividend at the moment.
How has YD Bio Limited Warrants stock done over the past year?
Down 75.1% over the past twelve months, to $0.51. It traded between $0.22 and $2.20 and is 77.0% below its high.
Who are YD Bio Limited Warrants's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with YD Bio Limited Warrants's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.